May 19, 2020
MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3 - a Potential New Gold Standard, First-line Treatment for Clostridium difficile Infection (CDI)
Mar 30, 2020
The Global Veterinary Clostridium Vaccine Market is expected to grow by USD 158.58 mn during 2020-2024, progressing at a CAGR of 5% during the forecast period
Jan 15, 2020
Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection
Nov 27, 2019
Global clostridium vaccine market is expected to grow with a CAGR of 4.50%% over the forecast period from 2019-2025
Nov 04, 2019
Acurx Pharmaceuticals to Present at Two Prominent International Healthcare Conferences
Oct 10, 2019
MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
Oct 01, 2019
Microbiome Therapeutics Innovation Group Highlights Member Company Activity at IDWeek 2019
May 17, 2019
Phase 3 Data of Collagenase Clostridium Histolyticum for the Investigational Treatment of Cellulite to Be Presented at The Aesthetic Meeting 2019
Mar 26, 2019
CutisPharma Continues Growth Trajectory with Opening of New Corporate Headquarters, Expansion of Manufacturing Site
Jan 24, 2019
MGB Biopharma - FDA and Health Canada Clear IND/CTA Applications for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
Jun 04, 2018
Rebiotix Microbiota Restoration Therapy(TM) Products, Microbiome Health Index(TM) to Take Center Stage at Digestive Disease Week 2018
Feb 26, 2018
TECHLAB® Products Identified As Meeting Updated Clinical Practice Guidelines For Clostridium Difficile Infection
Feb 20, 2018
New IDSA/SHEA Guidelines Highlight Critical Role of PCR Testing in C. difficile Diagnosis
Feb 05, 2018
Worldwide Clostridium Difficile Infection Treatment Market to Reach US$ 1,316.7 Mn by 2025 - Persistence Market Research
Nov 01, 2017
CutisPharma and C Diff Foundation Announce Partnership to Kick Off Clostridium difficile Awareness Month
Oct 16, 2017
New Clinical Data and Microbiome Research from Rebiotix's Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017
Jun 05, 2017
Ultra-Sensitive C. Difficile Assay In Development By Singulex Demonstrates Potential To Improve Diagnosis In Pilot Studies